MSD – known as Merck & Co in the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has been ...

These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

Merck is an industry giant that has proved time and again it can innovate for the future. Ventas has positioned itself to ...

New first-line option for patients with pMMR and dMMR tumours in England NICE has recommended KEYTRUDA (pembrolizumab) with ...

The UK’s National Institute for Health and Care Excellence (NICE) on August 6 recommended the use of US pharma giant Merck & ...

MRK scores an A+ grade for Profitability, aided by high gross and EBITDA margins of 78% and 46%, respectively. Moreover, it ...

WinRevair’s Phase 3 HYPERION trial was stopped early for efficacy, with positive top-line results announced in the month ...

The highest-paying dividend stocks in the Dow Jones Industrial Average right now are Verizon Communications (NYSE: VZ), ...

President Donald Trump provided new details about his plan to impose tariffs on foreign-made pharmaceuticals, but the White ...

The FDA's top regulator of cancer drugs interceded in a review of a Replimune skin cancer therapy, contributing to its ...

An artificial intelligence-based image analysis model has more accurately predicted cancer biomarkers and outcomes compared with conventional methods.

In an interview with CURE, Clara Cirk shares the emotional weight of finishing chemo while facing ongoing immunotherapy and ...